Serum Neuron Specific Enolase Level as a Prognostic Factor in Non-Small Cell Lung Cancer.

Andoh, Masahiro; Gemma, Akihiko; Takenaka, Kiyoshi; Hisakatsu, Shouji; Yamada, Kazutoyo; Usuki, Jiro; Hasegawa, Kouichi; Sakonji, Mitsuaki; Kudoh, Shoji; Tsuboi, Eitaka; Niitani, Hisanobu

doi:10.2169/internalmedicine.33.271

Cited by 9 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16][17][18][19] The elevation of serum neuron-specific enolase level was also reported in 40% to 60% of patients with SCLC and in 5% to 20% of patients with NSCLC. 17,18,20,21 Although the elevation of a serum level for these 2 makers was shown in the present study, it was not so frequent as was reported in SCLC. In terms of tumor markers, the pattern of elevation in serum level seemed to have some resemblance to those of NSCLC rather than those of SCLC.…”

Section: Discussioncontrasting

confidence: 59%

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases

Takei

Asamura

Maeshima

et al. 2002

The Journal of Thoracic and Cardiovascular Surgery

294

232

View full text Add to dashboard Cite

In terms of prognosis, large cell neuroendocrine carcinoma is distinctly different from other non-small cell lung cancers. The prognosis of large cell neuroendocrine carcinoma was poor, even for early stage disease; the prognosis of the stage I disease of large cell neuroendocrine carcinoma was poorer than that of the same stage of other non-small cell lung cancers. Because of its aggressive clinical behavior and poor prognosis, large cell neuroendocrine carcinoma should be recognized as one of the poorest prognostic subgroups among primary lung cancers, and therefore novel therapeutic approaches should be established.

show abstract

Section: Discussioncontrasting

confidence: 59%

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases

Takei

Asamura

Maeshima

et al. 2002

The Journal of Thoracic and Cardiovascular Surgery

294

232

View full text Add to dashboard Cite

show abstract

“…This finding was partially consistent with the finding that serum NSE levels depended on the tumor size and clinical stage in NSCLC. 33 Another report showed that serum NSE levels could reflect the status of tumor burden and might be increased after chemotherapy. 34 Therefore, we speculated that serum NSE levels seemed to be associated with the following two factors: first, the serum release of LCNEC cells with NSE was due to rapid tumor growth; and second, tumor aggressiveness and metastasis led to the destruction of LCNEC cells containing NSE.…”

Section: Discussionmentioning

confidence: 99%

Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma

Zhang¹,

Qin²,

Yin³

et al. 2015

OTT

View full text Add to dashboard Cite

BackgroundTo understand the clinicopathological features of patients with primary pulmonary large-cell neuroendocrine carcinoma (LCNEC), including the frequency of epidermal growth factor receptor (EGFR) mutation, and to explore prognostic factors.MethodsWe investigated a cohort of 50 individuals from our center database who were diagnosed with operable pulmonary LCNEC and treated in Sun Yat-sen University Cancer Center. Serum albumin (ALB) and neuron-specific enolase (NSE) were also collected. Survival curves were obtained with the Kaplan–Meier method, and the differences between groups in survival were tested by the log-rank test.ResultsThe median age was 59 years (range, 40–80 years). Fourteen patients underwent mutational analysis of EGFR; of these, 12 had wild-type EGFR and the remaining two had EGFR mutations in exons. The median disease-free survival (DFS) of pulmonary LCNEC was 49.3 months and that of overall survival (OS) was not reached. DFS and OS were shorter for patients with decreased serum ALB than for patients with normal serum ALB (P=0.003 and P=0.004, respectively). Meanwhile, a high level of NSE was also significantly associated with short DFS and OS (P=0.005 and P=0.000, respectively). Multivariate analysis showed that decrease in serum ALB was an independent prognostic factor for OS (P=0.046).ConclusionThe frequency of EGFR mutation in LCNEC patients is low. Serum ALB and NSE levels are valuable prognostic factors for LCNEC patients.

show abstract

“…In other histological classifications of NSCLC, elevated NSE might reflect its neuroendocrine differentiation or the presentation of SCLC components. In inoperable non-small cell lung cancer, some studies showed that a high serum NSE level was associated with a significantly worse prognosis (37)(38)(39)(40). N Viñolas and colleagues found that a high pretreatment serum NSE level was associated with a more probability of response to treatment although it was also associated with a worse prognosis (41).…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types

Chen

Zhao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesTo assess the association between common-used serum tumor markers and recurrence of lung adenocarcinoma and squamous cell carcinoma separately and determine the prognostic value of serum tumor markers in lung adenocarcinoma featured as ground glass opacities.MethodsA total of 2,654 non-small cell lung cancer patients undergoing surgical resection between January 2008 and September 2014 were analyzed. The serum levels of carcinoma embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carbohydrate antigen 199 (CA199) were tested preoperatively. Survival analyses were performed with COX proportional hazard regression.ResultsAmong patients with lung adenocarcinoma, elevated preoperative serum CEA(HR=1.246, 95%CI:1.043-1.488, P=0.015), CYFRA21-1(HR=1.209, 95%CI:1.015-1.441, P=0.034) and CA125(HR=1.361, 95%CI:1.053-1.757, P=0.018) were significantly associated with poorer recurrence free survival (RFS). Elevated preoperative serum CA199 predicted worse RFS in patients diagnosed with lung squamous cell carcinoma (HR=1.833, 95%CI: 1.216-2.762, P=0.004). Preoperative serum CYFRA21-1(HR=1.256, 95%CI:1.044-1.512, P=0.016) and CA125(HR=1.373, 95%CI: 1.050-1.795, P=0.020) were independent prognostic factors for patients with adenocarcinoma presenting as solid nodules while serum CEA (HR=2.160,95%CI:1.311-3.558, P=0.003) and CA125(HR=2.475,95%CI:1.163-5.266, P=0.019) were independent prognostic factors for patients with adenocarcinoma featured as ground glass opacities.ConclusionsThe prognostic significances of preoperative serum tumor markers in non-small cell lung cancer were associated with radiological features and histological types.

show abstract

Serum Neuron Specific Enolase Level as a Prognostic Factor in Non-Small Cell Lung Cancer.

Cited by 9 publications

References 15 publications

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases

Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma

The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types

Contact Info

Product

Resources

About